Cancer of the nasopharynx

Lisa Licitra, Jacques Bernier, Esteban Cvitkovic, Cesare Grandi, Silvia Spinazzé, Paolo Bruzzi, Gemma Gatta, Roberto Molinari

Research output: Contribution to journalArticlepeer-review


Nasopharyngeal cancer (NPC) is quite rare throughout Europe, accounting for an annual incidence rate below 1 per 100.000, whereas the highest risk area is South East Asia. A predominant occurrence in males is to be noted. NPC is an etiologically multifactorial disease, most probably involving viral, genetic and environmental factors. Carcinomas of the nasopharynx can be divided into two major histotypes: keratinizing squamous cell carcinomas (WHO-type 1) and non-keratinizing carcinomas (WHO-type 2). The histological type is a prognostic factor and it has a clear impact on the outcome of treatment. Standard therapeutic option for early stages of NPC is radiation, while an integration of radiation therapy and chemotherapy is indicated in more advanced stages.

Original languageEnglish
Pages (from-to)199-214
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - Feb 1 2003


  • Chemotherapy
  • Nasopharynx
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Cancer of the nasopharynx'. Together they form a unique fingerprint.

Cite this